Exercise for Menopause Sex Drive: What Actually Helps

Exercise improves several components of menopausal sexual function: blood flow, mood, body confidence, energy and pelvic floor function, with measurable improvements documented across multiple controlled trials. Carcelén-Fraile and colleagues’ 2020 systematic review in Maturitas on physical activity and sexual function in postmenopausal women pooled trials of resistance training, aerobic exercise and mind-body interventions, finding consistent improvements in sexual function scores after 12+ weeks of structured training. Exercise alone doesn’t resolve every cause of low menopausal libido (vaginal symptoms, hormonal changes, relationship factors and mental health all matter independently), but it addresses several mechanisms simultaneously and is one of the most evidence-backed adjunctive interventions available.

At a glance: exercise and menopausal libido

Intervention	What it improves	Practical take
Resistance training, 2-3x/week	Body confidence, mood, testosterone-mediated libido pathway	Foundation. Strongest single intervention.
Aerobic exercise, 150 min/week	Blood flow, cardiovascular response, mood	Walking and Zone 2 count. Daily dose.
Pelvic floor exercises, daily	Pelvic blood flow, sexual sensation, function	Often missing piece. 10 minutes a day.
Yoga and breathwork	Stress reduction, mind-body awareness, anxiety reduction	Useful adjunct. Particularly for stress-driven low libido.
Treating sleep disruption	Energy, mood, hormonal regulation	Foundational. Tired women rarely have high libido.
Vaginal oestrogen (with GP)	Vaginal dryness, comfort, sexual function	Standalone treatment for genitourinary symptoms.
HRT consideration	Vasomotor symptoms, mood, vaginal symptoms, sometimes libido	Discuss with menopause-trained GP if symptoms warrant.
Communication with partner	Relationship satisfaction, sexual frequency	Often the biggest single factor.

Why menopause affects sex drive

Sex drive in menopause is affected by multiple overlapping factors: hormonal changes (oestrogen, testosterone, progesterone), genitourinary syndrome of menopause (vaginal dryness and discomfort), mood and energy effects of perimenopause, sleep disruption, body image changes, and relationship and life-stage factors. Worsley and colleagues’ 2017 study in Sexual Medicine documented that roughly 40-50% of midlife women report low sexual desire, with the multifactorial nature of the cause being the central feature [1]. Davis and colleagues’ 2015 Lancet menopause review covered the sexual symptom cluster as one of the major and under-addressed elements of the menopausal experience [2].

The hormonal pathway has several components. Oestrogen affects vaginal tissue health, sexual response, and mood. Its decline contributes to vaginal dryness and discomfort that can make sex physically uncomfortable. Testosterone, which is produced in smaller amounts in women than men but still affects libido, declines gradually from the 30s onwards, with a more substantial drop at and after menopause. Progesterone affects mood and sleep, both of which influence sexual interest indirectly.

The genitourinary syndrome of menopause (GSM) is the cluster of vaginal and urinary symptoms driven by oestrogen loss in vaginal and urinary tissue. Vaginal dryness, thinning of vaginal walls, reduced elasticity, increased pH, and sometimes urinary symptoms. GSM affects roughly 50-70% of postmenopausal women but is often under-discussed in clinical settings. The symptoms can make sex physically uncomfortable, which secondarily affects desire. Treatment for GSM (vaginal moisturisers, lubricants, vaginal oestrogen) is highly effective and addresses one of the most common physical contributors to menopausal sexual symptoms.

The mood and energy pathway is significant. Depression and anxiety reduce sexual interest independently of hormonal changes. Chronic fatigue from disrupted sleep affects libido predictably. The cumulative effect of multiple perimenopausal symptoms (vasomotor, mood, sleep, joint pain, brain fog) often produces a baseline of feeling unwell that makes sexual interest hard to access.

The body image pathway matters. Body composition changes through menopause (the abdominal fat redistribution covered in the menopause weight gain guide, the muscle loss covered in the sarcopenia guide) often affect women’s relationship with their own body and consequently their sense of being a sexual person. The shift can be navigated with self-compassion or it can become a barrier; either way it’s part of the picture.

The relationship pathway is often underdiscussed in medical settings but is consistently identified as a major predictor of midlife sexual function in research. Length of relationship, sexual communication, partner’s own sexual function, division of household labour, and emotional intimacy all affect sexual satisfaction independently of biology. Sex therapists and relationship counsellors have established frameworks for working with these factors that exercise alone can’t address.

Why exercise actually helps menopausal sex drive

Exercise improves menopausal sexual function through five pathways: improved blood flow including to genital tissue, mood and anxiety reduction, body confidence and self-efficacy gains, energy and sleep improvements, and pelvic floor function (when pelvic floor work is included). Carcelén-Fraile 2020 mapped these mechanisms in their systematic review and found consistent improvements across multiple sexual function domains after 12+ weeks of structured training in postmenopausal women.

The blood flow pathway is direct and well-documented. Regular cardiovascular exercise improves endothelial function, increases nitric oxide availability, and improves blood flow to all tissues including genital tissue. Sexual arousal is fundamentally a vascular event: improved baseline circulation supports the physiological response. Lorenz and Meston’s work has demonstrated that acute exercise can directly improve genital arousal response in women, with the effect emerging within 30 minutes of exercise.

The mood pathway operates through the same mechanisms covered in the dedicated menopause anxiety and mood guide. Exercise reduces anxiety and improves mood with effect sizes comparable to first-line pharmacotherapy in some trials. Lower anxiety and better mood translate to improved sexual interest. The Schuch 2016 meta-analysis on exercise and depression and the Stubbs 2017 review on exercise and anxiety both document large effects that bear directly on the libido picture.

The body confidence pathway is harder to measure but consistently reported. Women who train regularly and see strength and body composition improvements typically report better body image and sexual self-efficacy. The mechanism is partly objective (actual physical changes), partly subjective (the experience of capability and progress), and partly relational (the visible commitment to physical health that often shifts a partner’s perception too).

The energy and sleep pathway closes the loop. Tired women rarely have high libido. The Erickson and Spiegel sleep literature documents how sleep disruption affects mood, hormones and energy. Regular exercise improves sleep quality (covered in the menopause insomnia guide), which improves energy and mood, which supports sexual interest. The cascade runs through multiple systems but the net effect is consistent.

The pelvic floor pathway is specific to including pelvic floor exercises in the training week. Pelvic floor strength and function affect both sexual sensation and confidence. Pelvic floor exercises improve blood flow to the area, support the muscles involved in arousal and orgasm, and address the urinary symptoms that often co-occur with sexual symptoms. This is a small daily addition with disproportionate effect on the symptom cluster.

Strength training, mood and body confidence

Strength training is the single highest-evidence exercise intervention for the body confidence and mood components of menopausal sexual function, with the documented effects on depression, anxiety and self-efficacy translating consistently to sexual function improvements. The Gordon 2018 JAMA Psychiatry meta-analysis on resistance training and depressive symptoms documented a moderate effect across 33 trials [3]. The body composition and visible muscle changes from progressive strength training over 12+ weeks shift body image and sexual self-efficacy in directions that other interventions don’t reliably match.

The mechanism is multi-pathway. Acute resistance training elevates testosterone modestly, with the effect larger and more sustained in women who train consistently than in untrained women. The body composition changes (more muscle, less fat in the abdominal region specifically) shift body image. The self-efficacy gains from progressive overload (lifting weights you couldn’t lift six weeks ago) generalise to other domains including sexual confidence. The mood and anxiety effects are documented in the broader strength-and-mood literature.

What does this look like practically? The same 2-3 strength sessions per week, full-body or upper/lower split, compound movements with progressive overload that produce the muscle, bone and metabolic outcomes covered in the strength training guide. The libido benefits emerge as side effects of the same training, typically becoming visible at 8-12 weeks alongside the body composition and strength changes.

For women whose sexual concerns include feeling disconnected from their body, strength training has the additional benefit of producing a different relationship with the body. The body becomes the source of capability and progress rather than just an object to evaluate. This shift is hard to achieve through purely cognitive interventions and emerges naturally through consistent strength training over months.

Programmes that fit this brief include Caroline Girvan CGX (7.8), Burn360 (8.3) and EvolveYou (6.0). The structural feature that matters is progressive overload that produces visible strength and body composition changes over months.

Cardiovascular fitness and sexual response

Regular cardiovascular exercise improves blood flow to all tissues including genital tissue, supports the vascular component of sexual arousal, and contributes to the mood and energy infrastructure that sexual interest sits on. The mechanisms are the same that drive cardiovascular protection more broadly: improved endothelial function, increased nitric oxide availability, better vascular reactivity. Sexual arousal is fundamentally a vascular event, and improved baseline circulation supports the physiological response.

The acute effect was documented in Lorenz and Meston’s research on exercise and sexual arousal in women. They found that 20 minutes of moderate-intensity exercise produced measurable improvements in genital arousal response in subsequent laboratory testing, with the effect mediated through autonomic nervous system activation. The chronic effect compounds over weeks of consistent training as cardiovascular fitness improves and baseline circulation strengthens.

The dose that produces these effects is the same that produces the broader cardiovascular benefits: 150 minutes of moderate-intensity cardio per week, distributed across 3-5 sessions. Walking, cycling, swimming and other Zone 2 modalities all work. The dedicated Zone 2 cardio guide covers the dose mathematics.

The acute pre-sex effect is worth knowing about practically. Some women find that exercise within 6-12 hours before planned sexual activity supports physical arousal response. This isn’t a prescription; it’s an observation that the autonomic nervous system primed by recent exercise often produces stronger physiological response. Individual variation is large; experimentation is the only way to know whether this applies to any individual woman.

What I’d avoid: assuming that adding more cardio fixes everything. The dose-response curve for cardio and sexual function isn’t linear; the basic threshold (150 minutes per week of moderate cardio) captures most of the benefit. Adding hours of additional cardio at the expense of strength, sleep or recovery often makes the broader picture worse rather than better.

Pelvic floor exercises and sexual function

Pelvic floor exercises improve sexual sensation, support arousal response, and address the urinary symptoms that often co-occur with sexual symptoms in postmenopausal women. Ten minutes of daily pelvic floor work is a small addition with disproportionate effect on the menopausal sexual symptom cluster. The pelvic floor exercises guide covers the protocol in detail; the libido-specific implications are covered here.

The mechanism involves several pathways. Pelvic floor strength supports the muscles directly involved in arousal and orgasm. Pelvic floor exercises improve blood flow to the genital region, supporting the vascular component of sexual response. Stronger pelvic floor reduces the urinary symptoms (urgency, stress incontinence) that often discourage sexual activity. The cumulative effect on sexual function is consistent across trials.

What does this look like practically? Daily pelvic floor work, ideally split into multiple short sessions (5 minutes morning, 5 minutes evening) rather than one longer session. The exercises include slow contractions (3-5 seconds hold, 3-5 seconds release) and quick contractions (1 second on, 1 second off), 10-15 repetitions of each, performed in different positions (lying, sitting, standing). Most women benefit from initial assessment and coaching from a women’s health physiotherapist to confirm correct technique.

For women whose pelvic floor symptoms are significant (incontinence, prolapse, persistent pelvic pain), specialist physiotherapy assessment is more valuable than self-directed exercise. The condition warrants individualised assessment and may require treatments beyond exercise alone (vaginal pessaries, surgical options for severe prolapse, medication for overactive bladder).

For women without significant symptoms, daily pelvic floor exercises are essentially preventive: maintaining function before symptoms develop, supporting sexual function as part of broader physical training, and addressing the subtle changes that perimenopausal hormonal shifts produce in pelvic tissue.

Yoga, stress reduction and the mind-body connection

Yoga and stress reduction practices improve menopausal sexual function through reduced anxious arousal, improved interoceptive awareness, and the parasympathetic activation that supports sexual response. The evidence for yoga and sexual function is reasonable but not as strong as the strength training and aerobic evidence; yoga’s value here is as an adjunct rather than as the primary intervention.

Brotto and colleagues at the University of British Columbia have documented that mindfulness-based interventions improve sexual desire and arousal in women, particularly women whose sexual symptoms include difficulty with mental engagement during sexual activity. The mechanism appears to be improved interoceptive awareness (the ability to attend to physical sensations) and reduced cognitive interference (the mental noise that pulls attention away from sexual stimuli).

For perimenopausal women specifically, the anxiety reduction and sleep support that yoga provides bear on the libido picture indirectly. Lower baseline anxiety and better sleep produce better mood and energy, which produce better sexual interest. The Newton 2014 yoga and menopausal symptoms trial documented improvements in mood, sleep and quality-of-life scores that bear on sexual function as a downstream effect [4].

Mindfulness training (meditation, body scan practices, mindfulness-based stress reduction or MBSR) produces similar effects through the same mechanisms. Carmody and colleagues’ 2011 trial on MBSR for hot flashes documented improvements in stress, sleep and quality of life that affect the broader symptom cluster including sexual function indirectly.

What works practically: 1-2 yoga or mindfulness sessions per week as a complement to a strength and cardio foundation. Slow restorative or yin styles are particularly useful for stress reduction; vigorous styles produce more cardio benefit but less direct stress-reduction benefit. The choice depends on personal preference and broader training mix.

The dose that produces sexual function improvements

The dose that consistently produces sexual function improvements in the trial literature is 2-3 strength sessions per week plus 150 minutes of moderate aerobic activity plus daily pelvic floor work, sustained for at least 12 weeks. This dose meets the WHO physical activity guidelines and matches the volumes used in most positive sexual function trials in postmenopausal women including Carcelén-Fraile 2020 and related work.

The intensity question is similar to the broader exercise prescription for women over 40. Moderate aerobic intensity (Zone 2) provides the cardiovascular and blood flow benefits. Resistance training intensity should be challenging enough to drive adaptation (RPE 7-8). Pelvic floor work doesn’t require external load; the intensity comes from the technique and the contraction quality.

Frequency matters. Daily walking plus 2-3 strength sessions plus daily pelvic floor work distributes the cues across the week and produces stronger cumulative effect than concentrated training in 2-3 sessions. The pattern that works for general health works for sexual function too.

The timeline matters. Sexual function improvements typically emerge at 8-12 weeks of consistent training, with continued improvement over 6-12 months as body composition changes and confidence shifts compound. Trainees who stop at week 4 because nothing has obviously changed cut themselves off before the largest benefits arrive.

How long until sexual function improves

Energy and mood improvements typically emerge within 4-6 weeks of consistent training, with sexual function improvements following over 8-16 weeks as body composition, confidence and pelvic floor function shift. The trial literature consistently measures sexual function outcomes at 12-16 weeks, which is the meaningful evaluation point.

The progression often runs through a predictable sequence. Weeks 1-2 are mostly nervous-system adaptation and routine establishment; nothing obvious shifts yet. Weeks 3-6 bring noticeable improvements in energy, mood and sleep, which often translate to slightly improved sexual interest as a secondary effect. Weeks 6-12 are when the body composition and strength changes start to shift body image and confidence. Weeks 12-26 are when the cumulative changes become obvious and sexual function improvements are typically reported in trial measurements.

Reasonable benchmarks to track over 12 weeks:

• Energy across the day: subjective 1-10 daily. Should trend up.
• Mood stability: subjective rating. Should improve.
• Sexual interest frequency: private notes on how often sexual thoughts or interest arises. Should increase.
• Body image: subjective 1-10 on how you feel about your body. Should improve.
• Physical comfort during sexual activity: if vaginal symptoms are present, separate measurement.

Don’t expect linear progression. Sexual function follows a fluctuating trend even on a working intervention, and the relational and life-stress factors affect it independently of biology. The trend across 4-week rolling averages is the metric that matters.

When exercise isn’t enough: HRT, vaginal symptoms and the relationship picture

Exercise improves several components of menopausal sexual function but doesn’t fully address vaginal dryness or genitourinary syndrome of menopause, severe hormonally-driven low libido, mental health conditions, or relationship factors. Each of these has its own evidence-based interventions that work alongside exercise rather than being replaced by it.

For genitourinary syndrome of menopause (vaginal dryness, discomfort, urinary symptoms), the first-line treatment is local vaginal oestrogen, which restores tissue health with minimal systemic absorption. The British Menopause Society and The Menopause Society both publish guidance positioning vaginal oestrogen as appropriate for nearly all postmenopausal women with GSM symptoms, including women who can’t or don’t want systemic HRT. Vaginal moisturisers and lubricants address the symptoms partially without affecting the underlying tissue health.

For severe hormonally-driven low libido, testosterone therapy is increasingly recognised as a treatment option for postmenopausal women who don’t respond to other interventions. The British Menopause Society 2022 guidance on testosterone replacement in women provides current clinical positioning. Testosterone therapy in women is off-label in many contexts and the decision is between you and a menopause-trained GP based on full assessment.

For mental health conditions affecting libido (depression, anxiety, trauma history), treatment of the underlying condition is the primary intervention. Psychological therapy (CBT, EMDR for trauma history, sex therapy) and medication where appropriate address causes that exercise can’t fully resolve. The dedicated menopause anxiety and mood guide covers the mental health intersection.

For relationship factors, sex therapy and relationship counselling have established frameworks for working with the issues that affect midlife sexual function. Length of relationship, sexual communication, partner’s own sexual function, and the practical logistics of sex in midlife all matter and often respond better to communication and structured therapy than to anything physical.

Red flags worth raising with a GP rather than trying to address through exercise alone:

• Painful sex that doesn’t resolve with lubricant use.
• Vaginal bleeding after sex (always warrants gynaecological assessment).
• Severe loss of sexual interest distressing to you, lasting more than three months.
• Sexual pain not associated with menopausal vaginal changes.
• Concurrent depression or anxiety warranting separate treatment.
• Relationship distress that exercise alone won’t resolve.

A sample week for menopausal sexual function

Here’s a 7-day template combining the strongest evidence-backed interventions for menopausal sexual function: 3 strength sessions, daily walking, 1 yoga session, daily pelvic floor work, 2 genuine rest days. Adjust to your fitness baseline.

Day	Main session	Pelvic floor work
Monday	Strength: full-body, 40 min	5 min morning + 5 min evening
Tuesday	Brisk walk 30-45 min	5 min morning + 5 min evening
Wednesday	Strength: full-body, 40 min	5 min morning + 5 min evening
Thursday	Yoga or restorative session, 30 min	5 min morning + 5 min evening
Friday	Strength: full-body, 40 min	5 min morning + 5 min evening
Saturday	Long walk or hike, 60-90 min	5 min morning + 5 min evening
Sunday	Rest or gentle mobility	5 min morning + 5 min evening

Why this structure? Three strength sessions cover the body confidence and mood effects. The walking provides the cardiovascular and blood flow benefits. The yoga session covers the stress reduction and mind-body component. The daily pelvic floor work addresses the local function and sensation. Two rest days protect against the cortisol-driven anxiety that worsens libido in this age range.

Programmes that fit menopausal sexual function support

The programmes that work best for menopausal sexual function support share three features: strength training as the foundation, low-impact options for women with joint or pelvic considerations, and reasonable session lengths that fit alongside the rest of life. Below are the platforms reviewed at herdailyfit.com/programs that fit this brief.

Caroline Girvan CGX (7.8). Heavy compound strength, four sessions a week. Builds the strength and body composition changes that affect body image. Full review at the CGX programme page.

Pvolve (8.7). Resistance-band-based, low-impact, with structured progressions. Pvolve specifically includes pelvic floor and core work integrated into many sessions, which matches this guide’s pelvic floor recommendation. Full review at the Pvolve programme page.

The Sculpt Society (8.6). Pilates-leaning, lower-load, easy on joints. Includes pelvic floor and core integration. Full review at the Sculpt Society programme page.

Burn360 (8.3). 20-25 minute strength sessions leave time for walking, yoga and pelvic floor work alongside. Full review at the Burn360 programme page.

For dedicated pelvic floor programmes, in-person assessment with a women’s health physiotherapist is usually more valuable than app-based generic programmes. The technique calibration matters more than the routine itself.

Common mistakes

Five common mistakes compromise the libido-supporting effects of exercise: ignoring pelvic floor work, over-training and worsening anxiety, focusing only on cardio, treating exercise as the complete solution, and abandoning the intervention before the body composition and confidence changes accumulate.

Ignoring pelvic floor work misses one of the highest-yield small interventions available. Daily pelvic floor exercises take 10 minutes and address sexual function and urinary symptoms simultaneously. Most women in this category aren’t doing them; the fix is starting.

Over-training and worsening anxiety is the configuration that most often makes libido worse rather than better through exercise. Five HIIT sessions a week without recovery infrastructure raises baseline cortisol and worsens mood, which worsens libido. The fix is reducing training load to 3-4 sessions plus walking, with proper rest days.

Focusing only on cardio leaves the body composition, strength and mood pathways under-stimulated. Strength training is the foundation; cardio is the complement. Reverse the priority for better libido-related outcomes.

Treating exercise as the complete solution misses the multifactorial nature of menopausal sexual symptoms. Vaginal dryness needs vaginal oestrogen or moisturiser. Hormonal contributors may warrant HRT consideration. Mental health conditions need their own treatment. Relationship factors need communication and sometimes therapy. Exercise is part of the picture, not the whole picture.

Abandoning at week 4 because nothing has obviously changed cuts trainees off before the largest benefits arrive. Sexual function improvements typically emerge at 8-12 weeks alongside the body composition and confidence shifts. Twelve weeks is the minimum useful test.

Vaginal symptoms and what reliably treats them

Vaginal dryness, thinning, reduced elasticity and discomfort during sex affect roughly 50-70% of postmenopausal women, and are reliably treatable through vaginal oestrogen, lubricants and moisturisers, with vaginal oestrogen being the most effective single intervention. The symptom cluster is termed Genitourinary Syndrome of Menopause (GSM) and is one of the most under-discussed yet highly treatable aspects of menopausal sexual function.

Vaginal oestrogen comes in several formulations: low-dose vaginal oestrogen tablets (Vagifem), creams (Premarin, Ovestin), or rings (Estring). The active ingredient acts locally on vaginal tissue with minimal systemic absorption, restoring tissue health, hydration and elasticity. The British Menopause Society and The Menopause Society both position vaginal oestrogen as appropriate for nearly all postmenopausal women with GSM symptoms, including women who can’t or don’t want systemic HRT and including breast cancer survivors after specialist discussion. Treatment is well-tolerated and effective; most women see meaningful symptom improvement within 4-12 weeks.

Vaginal moisturisers (Replens, YES VM, Hyalofemme) provide longer-acting hydration through the vaginal tissue. Used 2-3 times per week independent of sexual activity, they support baseline tissue moisture. Moisturisers don’t replace oestrogen but provide useful adjunct support.

Lubricants used during sexual activity address acute friction and discomfort. Water-based, silicone-based, and hybrid options each have specific use cases. For women using condoms or sex toys, water-based or hybrid (avoid silicone with silicone toys) is appropriate. Avoid lubricants with parabens, glycerin or fragrance for women with sensitive vaginal tissue. Ample lubricant use during sex is appropriate at any age and shouldn’t be viewed as failure or compromise.

For women whose vaginal symptoms persist despite oestrogen and lubricant use, additional options include vaginal laser therapy (mixed evidence, expensive, not first-line), pelvic floor physiotherapy if symptoms include muscle tension, and specialist menopause clinic referral. The dedicated pelvic floor guide covers the muscle component.

The relationship context: communication, connection and shared bodies

Sexual function in midlife is as much relational as it is physiological. Length of relationship, sexual communication patterns, partner’s own sexual function, division of household labour, and emotional intimacy all affect sexual interest and satisfaction independently of biology. Exercise improves several physiological components; addressing the relational components requires different work that exercise alone can’t substitute for.

The communication piece is often where the most leverage sits. Many midlife couples haven’t actively discussed their sexual relationship in years; preferences, desires, and what’s changed are assumed rather than communicated. Sex therapists routinely document that couples who develop communication patterns about sexual preferences in midlife report substantial improvements in satisfaction independently of frequency or other variables.

The partner’s situation matters too. Partners experience their own physiological and life-stage changes. Male partners in this age range often have erectile function changes (typical, treatable, often unspoken), libido changes related to their own life stage, or stress-related sexual changes. Same-sex partners share the menopausal transition with different dynamics. The mutual experience and willingness to discuss it shapes how each individual experiences their own sexual changes.

The household labour piece is empirically connected to sexual function in heterosexual relationships specifically. Women who carry disproportionate household and childcare load report lower sexual desire and satisfaction; redistribution of load is associated with improvements. This is not advice to demand chore changes for sexual reasons; it’s acknowledging that the dynamic is real and addressing equity broadly affects multiple aspects of relationship including sexual.

For couples whose sexual relationship has become difficult to discuss directly, structured therapy provides scaffolding. Sex therapists, relationship counsellors, and approaches like Sue Johnson’s Emotionally Focused Therapy have established frameworks for the conversations that produce change. The cost is often modest; the impact across years can be substantial.

Testosterone in postmenopausal women: an emerging conversation

Testosterone supplementation for postmenopausal women with low libido is increasingly recognised as a clinical option in women who don’t respond to standard interventions, with the British Menopause Society publishing 2022 guidance on appropriate prescribing. The conversation has moved from fringe to mainstream over the past decade as the evidence base has grown.

The biology: women produce testosterone throughout life, in smaller amounts than men but at clinically meaningful levels. Production declines gradually from the 30s onwards and drops more substantially in postmenopause. The decline contributes to the libido changes many women experience, alongside the oestrogen-related effects covered earlier in this guide.

The evidence: multiple randomised trials have documented modest but consistent improvements in sexual desire, arousal, satisfaction and orgasm frequency from physiological-dose testosterone replacement in postmenopausal women with low libido. The Davis 2019 global consensus statement on testosterone use in women summarised the evidence and recommended testosterone consideration for postmenopausal women with hypoactive sexual desire dysfunction not responding to other interventions.

The clinical context: testosterone for women is currently off-label in many jurisdictions (no women-specific testosterone product is licensed in the UK, for example, though specific formulations are available through specialist menopause clinics). The British Menopause Society 2022 guidance on testosterone replacement provides the clinical framework. Women interested in this option should discuss with a menopause-trained GP or specialist menopause clinic; routine GP services may not have current expertise.

The cautions: testosterone for women is appropriate for postmenopausal women with persistent low libido after standard interventions (HRT, addressing modifiable contributors, pelvic floor work, relationship considerations). It’s not appropriate as first-line treatment, and dosing matters substantially (excessive doses produce androgenic side effects). Specialist input is essential.

Medications that affect libido in midlife

Several medications commonly prescribed in midlife affect libido as a side effect, often unrecognised by both patient and prescriber. Reviewing current medications with a GP or pharmacist when libido changes is part of working up the issue.

SSRIs and SNRIs (commonly prescribed antidepressants) reduce libido in a substantial proportion of users. The mechanism is partly serotonin-mediated and partly direct effects on sexual response. For women whose libido changes coincide with antidepressant use, alternatives within the antidepressant category sometimes have lower sexual side-effect profiles (bupropion specifically tends to be more sexually neutral); discussing alternatives with a prescribing clinician is appropriate.

Hormonal contraception in perimenopause (some women in early perimenopause continue using contraception) can affect libido through suppression of testosterone production. Combined oral contraceptives have specific effects on sex hormone binding globulin that reduce free testosterone availability.

Blood pressure medications including beta-blockers and some diuretics can affect libido and sexual function. Statins have less impact than older fears suggested but occasional cases warrant assessment. Many other commonly prescribed medications have lower-frequency sexual side effects.

The pragmatic approach: if libido changes coincide with starting a new medication, raise the temporal connection with the prescriber. Often alternative medications with different side-effect profiles can address the underlying condition without the sexual impact.

Where the evidence is still evolving

Three areas of the menopause-libido-exercise literature are still genuinely under-studied: the optimal exercise dose for menopausal sexual function specifically, the interaction between HRT (particularly testosterone) and exercise on sexual outcomes, and which exercise modalities produce the largest sexual function effects in this population.

Most research on exercise and sexual function is conducted in mixed adult populations rather than in postmenopausal women specifically. The translation is reasonable but the menopause-specific dose-response data is still maturing.

The HRT-exercise interaction is interesting but under-studied. HRT can improve sexual function directly through addressing hormonal contributors; exercise improves several other components. Whether their effects are additive or synergistic in postmenopausal women hasn’t been studied in head-to-head designs.

The modality question (strength vs aerobic vs yoga vs pelvic floor) has reasonable comparative data in mixed populations but limited direct comparisons in postmenopausal women specifically. The Carcelén-Fraile 2020 review supports the multi-modal combination approach over any single-modality approach.

Glossary

Genitourinary syndrome of menopause (GSM): the cluster of vaginal and urinary symptoms driven by oestrogen loss. Includes vaginal dryness, thinning, reduced elasticity, and sometimes urinary symptoms.

HSDD: Hypoactive Sexual Desire Disorder. The clinical diagnosis for persistent low sexual desire causing personal distress.

Libido: sexual desire or drive. Influenced by hormonal, neurological, psychological and relational factors.

Pelvic floor: the group of muscles supporting the pelvic organs. Important for continence, sexual function and core stability.

Sexual response cycle: the physiological and psychological stages of sexual activity (desire, arousal, orgasm, resolution).

Testosterone: hormone with roles in libido in both sexes. Declines gradually from the 30s; further drop at and after menopause.

Vaginal oestrogen: local oestrogen treatment for genitourinary syndrome of menopause. Minimal systemic absorption; appropriate for nearly all postmenopausal women with GSM symptoms.

References

1. Worsley R, Bell RJ, Gartoulla P, Davis SR. Prevalence and predictors of low sexual desire, sexually related personal distress, and hypoactive sexual desire dysfunction in a community-based sample of midlife women. J Sex Med. 2017;14(5):675-686. PubMed: 28499520
2. Davis SR, Lambrinoudaki I, Lumsden M, et al. Menopause. Nat Rev Dis Primers. 2015;1:15004. PubMed: 27188659
3. Gordon BR, McDowell CP, Hallgren M, et al. Association of efficacy of resistance exercise training with depressive symptoms: meta-analysis and meta-regression. JAMA Psychiatry. 2018;75(6):566-576. PubMed: 29800984
4. Newton KM, Reed SD, Guthrie KA, et al. Efficacy of yoga for vasomotor symptoms: a randomized controlled trial. Menopause. 2014;21(4):339-346. PubMed: 24045673
5. Carmody JF, Crawford S, Salmoirago-Blotcher E, et al. Mindfulness training for coping with hot flashes: results of a randomized trial. Menopause. 2011;18(6):611-620. PubMed: 21372745
6. Schuch FB, Vancampfort D, Richards J, Rosenbaum S, Ward PB, Stubbs B. Exercise as a treatment for depression: a meta-analysis adjusting for publication bias. J Psychiatr Res. 2016;77:42-51. PubMed: 26978184
7. Stubbs B, Vancampfort D, Rosenbaum S, et al. An examination of the anxiolytic effects of exercise for people with anxiety and stress-related disorders: a meta-analysis. Psychiatry Res. 2017;249:102-108. PubMed: 28092779
8. Spiegel K, Tasali E, Penev P, Van Cauter E. Brief communication: sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann Intern Med. 2004;141(11):846-850. PubMed: 15583226
9. British Menopause Society. Tools for clinicians: testosterone replacement in women. Available at: thebms.org.uk
10. British Menopause Society. Tools for clinicians: genitourinary syndrome of the menopause. Available at: thebms.org.uk
11. NHS. Sex problems in women. Available at: nhs.uk
12. The Menopause Society. Sexual health and menopause. Available at: menopause.org
13. Capel-Alcaraz AM, García-López H, et al. Effects of resistance training on body composition and physical function in postmenopausal women: a systematic review and meta-analysis. 2022. PubMed: 35055015
14. Hackney AC. Stress and the neuroendocrine system: the role of exercise as a stressor and modifier of stress. Expert Rev Endocrinol Metab. 2006;1(6):783-792. PubMed: 16645310

Frequently Asked Questions

Last reviewed: 5 May 2026. Author: Katy Cole. Editorial methodology and programme testing notes available at herdailyfit.com/about.